logo
welcome
Biotech and Pharma Industry News | BioPharma Dive

Biotech and Pharma Industry News | BioPharma Dive

Cell and gene therapy investment, once booming, is now in a slump

Biotech and Pharma Industry News | BioPharma Dive
Summary
Nutrition label

88% Informative

Makers of cell and gene therapies have raised half of a billion dollars this year .

Investors and analysts say the drop-off is due to manufacturing and drug delivery challenges.

Six CAR-T cell therapies have been approved by U.S. regulators to treat cancer and, in some indications, their benefits can be dramatic.

But uptake of some of the approved therapies has been slow, especially as companies work through manufacturing bottlenecks.

VR Score

93

Informative language

96

Neutral language

28

Article tone

semi-formal

Language

English

Language complexity

64

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Affiliate links

no affiliate links